Betta Pharmaceuticals announced that the company received the “Drug Registration Certificate” for ensartinib hydrochloride capsules issued by the State Drug Administration and approved it to increase the adjuvant treatment indications for ALK-positive stage IB to stage IIB non-small cell lung cancer after surgery. This is the third indication approved by Ensartinib. Ensatinib is a new generation ALK inhibitor. It has previously been approved for second-line and first-line treatment. Adjuvant treatment studies after surgery showed that the 2-year disease-free survival rate reached 86.4%, reducing the risk of recurrence by 80%. This approval has had a positive effect on the company's revenue, and there is uncertainty about the sales situation.

Betta Pharmaceuticals announced that the company received the “Drug Registration Certificate” for ensartinib hydrochloride capsules issued by the State Drug Administration and approved it to increase the adjuvant treatment indications for ALK-positive stage IB to stage IIB non-small cell lung cancer after surgery. This is the third indication approved by Ensartinib. Ensatinib is a new generation ALK inhibitor. It has previously been approved for second-line and first-line treatment. Adjuvant treatment studies after surgery showed that the 2-year disease-free survival rate reached 86.4%, reducing the risk of recurrence by 80%. This approval has had a positive effect on the company's revenue, and there is uncertainty about the sales situation.